African American Health Disparities are associated with low Vitamin D - Grant Feb 2021

Does the High Prevalence of Vitamin D Deficiency in African Americans Contribute to Health Disparities?
Nutrients 2021, 13, 499. https://doi.org/10.3390/nu13020499
Bruce N. Ames 1, William B. Grant 2,* and Walter C. Willett

 Download the PDF from VitaminDWiki

Many of the charts and tables

Low Vitamin D increases health problems - independent of skin color

Pregnant while Black

Increase Health problems for Black males

Increase Heatlh Problems for Blacks

Nice summary of different types of health studies

Bruce N. Ames William B. Grant wbgrant at infionline.net, and Walter C. Willett ,

• Molecular and Cell Biology, Emeritus, University of California, Berkeley, CA 94720, USA; bnames at berkeley.edu
• Sunlight, Nutrition and Health Research Center, San Francisco, CA 94164-1603, USA
• Departments of Nutrition and Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; wwillett at hsph.harvard.edu
  and, Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

African Americans have higher incidence of, and mortality from, many health-related problems than European Americans. They also have a 15 to 20-fold higher prevalence of severe vitamin D deficiency. Here we summarize evidence that: (i) this health disparity is partly due to insufficient vitamin D production, caused by melanin in the skin blocking the UVB solar radiation necessary for its synthesis; (ii) the vitamin D insufficiency is exacerbated at high latitudes because of the combination of dark skin color with lower UVB radiation levels; and (iii) the health of individuals with dark skin can be markedly improved by correcting deficiency and achieving an optimal vitamin D status, as could be obtained by supplementation and/or fortification. Moderate-to-strong evidence exists that high 25-hydroxyvitamin D levels and/or vitamin D supplementation reduces risk for many adverse health outcomes including all-cause mortality rate, adverse pregnancy and birth outcomes, cancer, diabetes mellitus, Alzheimer's disease and dementia, multiple sclerosis, acute respiratory tract infections, COVID-19, asthma exacerbations, rickets, and osteomalacia. We suggest that people with low vitamin D status, which would include most people with dark skin living at high latitudes, along with their health care provider, consider taking vitamin D3 supplements to raise serum 25-hydroxyvitamin D levels to 30 ng/mL (75 nmol/L) or possibly higher.

Introduction

The vitamin D hormone controls the activity of thousands of protein-encoding human genes [1]. Therefore, optimum levels are likely to be important for health. Synthesis of vitamin D in human skin depends on solar UVB radiation, whose levels are low at high latitudes, as in the United States and Europe, and highest at equatorial latitudes [2]. High concentration of melanin, the brown-black pigment in skin, is appropriate for the high UV radiation dose regions such as in the tropical plains as it absorbs UVB radiation absorption, thereby reducing production of free radicals and destruction of folate, but permitting adequate vitamin D production [3]. At higher latitudes, where the UVB radiation dose is lower [2], the rate of synthesis of vitamin D correspondingly decreases, potentially disrupting many metabolic functions that depend on that vitamin and leading to poorer health.

Here we discuss various aspects of such latitude-skin color mismatch and health disparities. By latitude-skin color mismatch, we mean that skin pigmentation is not appropriate for the solar UV doses at various latitudes, either too dark as for African Americans. (Note that people of African descent have dark melanin, called eumelanin, while Anglo-Celtics have yellow-to-reddish melanin called pheomelanin.)

(defined as people living in the United States with some African ancestry) to efficiently produce vitamin D, or too light to protect against the harmful effects of UV radiation as for people living close to the equator, such as those with Anglo-Celtic ancestry in Australia. (Note that people of African descent have dark melanin, called eumelanin, while Anglo-Celtics have yellow-to-reddish melanin called pheomelanin.) This mismatch is particularly impactful in African Americans, whose dark skin is well adapted to the high UVB levels at low equatorial latitudes [3]. However, as a legacy of slavery and more recent migration, African Americans now reside at higher latitudes than in their ancestral environments. That geographic shift is largely responsible for a high prevalence of vitamin D deficiency (serum 25-hydroxyvitamin D (25(OH)D) levels < 20 ng/mL) in African Americans [4,5] independent of diet and other factors [6]. This high prevalence of deficiency potentially contributes to many health disparities. Because vitamin D deficiency can be easily remedied by supplementation or, to a lesser extent, fortification of food, the health implications of this deficiency are important to understand.

Many factors adversely affect the health of African Americans, including high rates of poverty [7], poor housing and residential environments [8], and lack of access to affordable health care. Living in racially segregated, poor neighborhoods also exposes residents to risk of crime [9], thereby limiting time spent outdoors, as well as reducing access to well-stocked grocery stores and pharmacies. Limited educational opportunities frequently result in having jobs with high social interaction and thus greater risk of COVID- 19. The high incarceration rate of African American males has resulted in many children being raised by single mothers. While these factors play important roles in racial health disparities and require sustained efforts to correct at individual and societal levels, vitamin D deficiency can be corrected rapidly and inexpensively. In this review we examine the potential health benefits of addressing this deficiency.

This narrative review considers the potential health effects of inadequate vitamin D in humans. Although the motivation for this review is the high prevalence of vitamin D deficiency in African Americans, we draw on the literature from all populations because our underlying biology is similar across all racial groups, even though the prevalence of exposures, here serum levels of 25(OH)D, can differ greatly. Thus, the findings have implications for other groups with darker skin and low 25(OH)D levels, such as US immigrants from Mexico and South Asia, and for European Americans with limited sun exposure. (The term European Americans is used to represent white, non-Hispanic Americans.)
When they are available, we cite meta-analyses or pooled primary data from multiple studies. Because ideal randomized trials are often difficult or impossible to conduct, conclusions regarding causality will usually need to be based on the weight of evidence from multiple types of study [10]. The strengths and limitations of the various approaches to determine relationships between vitamin D and health outcomes are presented in the Appendix. Ideally, vitamin D's health effects in populations with dark skin would be evaluated directly in such groups, but in most studies the number of such participants has been too small to evaluate separately. Nevertheless, we highlight studies of subgroups of African Americans and Hispanics (17% of the U.S. population) when available. We also pay special attention to subgroups with low baseline serum levels of vitamin D in randomized trials as this where an effect of supplementation may be expected to be seen; failure to do this may lead to misleading negative conclusions. In some randomized trials comparing vitamin D supplements with a placebo, those with low serum levels of 25(OH)D are excluded for ethical reasons and/or are treated, again potentially leading to misleading conclusions.

Current Status of Knowledge

Vitamin D: Synthesis and Metabolism

Vitamin D3 is synthesized in human skin by the UVB-dependent conversion of 7- dehydrocholesterol to vitamin D3 (herein referred to as vitamin D when used as a supplement). Vitamin D3 is then converted to 25(OH)D3, a precursor of the crucial vitamin D steroid hormone, 1,25-dihydroxyvitamin D3, or calcitriol, in a reaction requiring magnesium [11,12], which is widely deficient in the American diet [13]. Calcitriol binds to a specific binding protein, the vitamin D receptor (VDR). The resulting complex interacts with human DNA regulatory sequences known as vitamin D response elements (VDREs; 15 bases long), which reportedly vary in number between a few thousand to ten thousand [14,15]. VDREs respond specifically to calcitriol by activating or inactivating their adjacent genes [16-18]; this response may vary depending on the location of the VDRE and level of 25(OH)D [15]. The unusually large number of calcitriol-responsive DNA sites strongly suggests that sufficiently high 25(OH)D levels, which may vary by outcome are necessary for optimal health and longevity [16,19].

Evolution of Skin Pigmentation

Skin pigmentation is an evolutionary response to the intense solar UVB at low latitudes, where early humans evolved. Dark skin, through the presence of abundant melanin, protected humans living in Africa, southern India, and other parts of Asia against strong UVB, which causes severe sunburn, damages DNA, and destroys skin folate [3,2022]. According to a widely accepted hypothesis, people in ancient times moved from low to higher latitudes, and skin pigment evolved (by several mutations) to be lighter, depending on distance from the equator, permitting more efficient production of vitamin D [3,23-26]. Others have suggested that lighter skin resulted from the acquisition of genetic variants from populations that immigrated into northern Europe, but this is still compatible with production of vitamin D being the initial selective factor for these variants [27]. (These authors also hypothesize that variations in genes encoding for proteins responsible for the transport, metabolism and signaling of vitamin D provide alternative mechanisms of adaptation to a life in northern latitudes without suffering the consequences of vitamin D deficiency. However, such mechanisms and loss of melanin are not mutually exclusive, and in either case they would leave people of African descent now living in northern latitudes at risk of vitamin D deficiency.) The importance of solar exposure is illustrated by findings that Africans with dark skin living at low latitudes have levels of 25(OH)D of 29 to 46 ng/mL [28-30], that are substantially higher than those of African Americans (mean 25(OH)D ~16 ng/mL) [31]. These differences, and the similarity in levels of 25(OH)D in European Americans and Africans living in Africa, are shown in Figure 1 [32]. Thus, darker skin pigmentation in Africans living in Africa appears to allow adequate vitamin D synthesis while protecting against sunburn and other damage. Direct genetic evidence that melanin reduces synthesis of vitamin D is provided by findings that Nigerians with albinism have significantly higher 25(OH)D levels than those with normal pigmentation
. The interaction between skin melanin and sunlight was further illustrated in a study of pregnant women in the southeastern US; the ratios of winter-to-summer prevalence of vitamin D insufficiency were 3.58 (95% CI 1.64 to 7.81) for European-American, 1.52 (95% CI 1.18 to 1.95) for Hispanic, and 1.14 (95% CI 0.99 to 1.30) for African-American women
.
In contrast to the slow migration in ancient times, in more recent times there was rapid movement of equatorial Africans to various regions, such as North America, due to slave transport. When the destination is at higher northern latitudes than that of the ancestral country of origin, a mismatch between skin color and UV radiation occurs and lower UVB penetration of the skin to the layer with 7-dehydrocholesterol results in deficient endogenous vitamin D production. The consequent health problems can take years to manifest and thus are both subtle and insidious. A reverse mismatch occurs when lightskinned individuals move to low latitudes (e.g., an Irish person moving to Australia), resulting in increased risk for severe sunburn (and later, high rates of skin cancer). The reverse mismatch is recognized quickly and can be mitigated by using hats and sunscreen.

Prevalence of 25(OH)D Deficiency by Race/ethnicity Group

According to data from National Health and Nutrition Examination Survey (NHANES) 2001-2010, the prevalence of vitamin D deficiency (25(OH)D < 20 ng/mL) among those not taking vitamin D supplements was 75% for non-Hispanic blacks, 44% for Hispanics, and 20% for non-Hispanic whites (Figure 2), whereas severe deficiency (<10 ng/mL) was 17% in non-Hispanic blacks and only 1% in non-Hispanic whites [35]. Although definitions vary [36], there is consensus that levels below 10 ng/mL are a serious concern. A high prevalence of low 25(OH)D levels has also been documented in many other parts of the world [37-41].

Serum vitamin D, 25(OH)D, nmol/L (Endocrine Society Categories)
Figure 2. Prevalence of serum 25(OH)D levels in National Health and Nutrition Examination Survey (NHANES) survey, 2001-2010, by race/ethnicity category among nonusers of vitamin D supplements [35]. Additional calculations courtesy of X. Liu. Note: Divide by 2.5 to convert nmol/L to ng/mL.

Vitamin D and Health Outcomes

Most epidemiologic studies of vitamin D and health outcomes have used plasma or serum levels of 25(OH)D to measure vitamin D status. That approach has the advantage of integrating intake, solar exposure, skin color, and genetic factors. A single measure of 25(OH)D serves as a good measure of long-term status for an individual; however, the within-person correlation between 25(OH)D levels decreases as follow-up time increases [42]. Downstream metabolites of 25(OH)D are too variable over time to serve as a stable indicator of vitamin D status [43]. Other indicators of vitamin D status, such as parathyroid hormone, may improve our assessment [44], but have not yet been widely used in epidemiologic studies. Some studies have used vitamin D intake calculated from food intake, with or without supplements.

Skeletal Health

Adequate vitamin D has long been recognized as essential for bone health, and the 2011 Institute of Medicine (IOM) review of vitamin D requirements concluded that rickets and osteomalacia were the only established consequences of low vitamin D status [36]. Thus, the relation to osteomalacia served to set recommendations for vitamin D intake: the estimated average requirement (EAR—at which half the population is deficient and half is not) for serum 25(OH)D was set at 16 ng/mL. On this basis also, levels below 12 ng/mL were considered deficient, 12 to 20 ng/mL were considered “at risk of inadequacy”, and levels above 20 ng/mL were considered sufficient for 97% of the population. Other groups have defined deficiency as levels below 30 ng/mL [45]. Since 2011, much additional evidence has supported the important effects of vitamin D beyond bone health, and the relation between serum levels of 25(OH)D and these health outcomes cannot be assumed to be the same as that with osteomalacia.
Serum levels of 25(OH)D are positively associated with bone mineral density in both European Americans and African Americans [46], but Africans and African Americans have long been known to have higher bone mineral density (BMD) [47] and lower risk of fragility fractures than Europeans [48]. Possible mechanisms may be that African Americans have higher calcium retention, lower calcium excretion, and greater bone resistance

to parathyroid hormone than European Americans [47,49,50]. The reason why populations migrating from Africa to higher latitudes evolved to have weaker bones is unclear, but in the context of low UV radiation a trade-off for reductions in pelvic deformity and obstructed labor has been suggested [51]. Whatever the mechanisms, the greater bone strength of African Americans, and the assumption that the only consequence of low 25(OH)D levels is poor bone health, seems to have led many to believe that the low serum levels 25(OH)D in African Americans are not a concern. Notably, the 2011 IOM review of vitamin D did not emphasize the high prevalence of vitamin D deficiency in African Americans, even by their strictest definition of less than 12 ng/mL, and concluded that “requirements are being met by most if not all persons in both countries [US and Canada]”.
A finding of low levels of vitamin D-binding protein (VDBP) in African Americans, and thus presumably higher biologically active vitamin D, has been suggested as an explanation for healthy bone mass in African Americans despite low 25(OH(D level [52]. However, the report of low VDBP levels was subsequently shown to be an artifact of the monoclonal antibody assay used in that study; when measured by a polyclonal method or proteomic assay, levels of VDBP were similar in African- and European Americans [53]. This, and findings of much higher 25(OH)D levels in Africans living traditional lifestyles in equatorial regions, support the conclusion that the low levels of African Americans are not “natural” but due to environmental factors, primarily inadequate sun exposure.

Pregnancy and Early Development

Pregnant African-American women have higher risk of many pregnancy-related complications than European American or Hispanic women (Table 1).

Pregnant women with darker skin color have lower 25(OH)D levels than women with lighter skin [34,58-60]. Indirect support for a role of vitamin D in development is provided by the finding that during pregnancy, maternal serum levels of 1,25(OH)2D increase by 75% and those of 25(OH)D by about 30% [61]. The placenta plays a major role regarding these increases [62]. Further, when 1,25(OH)2D stimulates the vitamin D receptors, it can affect the expression of hundreds to thousands of genes [1,15], and fetal development is guided by gene expression.

1. Preeclampsia. In a meta-analysis of data from 27 randomized controlled trials (RCTs)

including 4777 participants, vitamin D treatment reduced risk of preeclampsia by 63% (OR = 0.37 (95% CI, 0.26 to 0.52)) [63]. Results were similar with respect to beginning of supplementation, supplementation until delivery, whether or not calcium was also supplemented, and whether the trial was blinded. Increased vitamin D dosage up to 7000 IU/d was associated with reduced risk of preeclampsia.

1. Low birth weight and small for gestational age. In a meta-analysis of 24 RCTs involving 5405 participants, vitamin D supplementation (800 to 7000 IU/day) during pregnancy reduced risk of offspring being small for gestational age by 28% (Risk ratio = 0.72 (95% CI, 0.52 to 0.99, p = 0.04)) [64]. In an observational study conducted in Cincinnati involving 276 black infants and 162 white infants, cord blood vitamin D deficiency was associated with being small for gestational age for black infants (OR = 2.4 (95% CI, 1.0 to 5.8, p = 0.04)) but not white infants (OR = 1.1 (95% CI, 0.3 to 3.9, p = 0.86)) [65]. Vitamin D deficiency was associated with increased risk of preeclampsia among both black and white women: for blacks, OR = 2.3 (95% CI, 1.0 to 5.4, p = 0.04) and for whites, OR = 4.1 (95% CI = 1.0, 16.1, p = 0.05),
2. Preterm birth. In a meta-analysis of 18 observational studies, maternal 25(OH)D level <20 ng/mL versus >20 ng/mL was associated with a pooled OR = 1.25 (95%CI: 1.13 to 1.38) of preterm delivery [66]. In five studies, this was also the case for spontaneous preterm delivery; for 25(OH)D < 20 ng/mL vs. >20 ng/mL pooled OR = 1.45 (95% CI, 1.20 to 1.75). In a meta-analysis of six RCTs, involving 1880 participants with a total of 77 preterm births, vitamin D supplementation reduced preterm delivery by 43%; the pooled relative risk was 0.57 (95%CI: 0.36 to 0.91)) [66]. The vitamin D dose varied from 400 IU/d to 4000 IU/d. An open-label vitamin D supplementation study involving 1064 pregnant women including African-American and Hispanic and European- American women was conducted in South Carolina [67]. Women were counseled during their first prenatal visit on how to achieve >40 ng/mL 25(OH)D and given free bottles of 5000 IU vitamin D3. In the fully-adjusted model, achieving >40 ng/mL vs. <20 ng/mL resulted in an OR for preterm delivery of 0.41 (95% CI, 0.24 to 0.72). Significantly lower risks of preterm birth were seen for both white and non-white women.
3. Neurologic development. In 2008, vitamin D deficiency during pregnancy was hypothesized to be a risk factor for autism [68]. In a meta-analysis of 25 observational studies, higher vs. lower serum levels of 25(OH)D during pregnancy or in newborn blood at birth were associated with a 28% lower risk of attention deficit-hyperactivity disorder in the offspring [pooled relative risk = 0.72 (95% CI = 0.59 go 0.89, p = 0.002)] and a 58% lower risk of autism-related traits (pooled relative risk = 0.42 (95% CI = 0.25 to 0.71, p = 0.001)) [69]. Vitamin D supplementation during pregnancy has reduced risk of abnormal neurologic development, and administration of 4000 IU/d during pregnancy caused no adverse effects in a trial conducted in South Carolina [61,70].
4. Cesarean delivery. In an observational study in Boston involving 253 women of whom 43 had a cesarean delivery, women with serum 25(OH)D levels lower than 15 ng/mL at time of delivery had 3.8 times the rate of primary cesarean delivery as compared to women with higher levels [71].
5. The overall evidence strongly supports the harmful nature of vitamin D deficiency among pregnant women for both pregnancy-related outcomes and for fetal development. Further, vitamin D supplementation has reduced the risk of pregnancy-related complications, particularly for women with severe deficiency [72].

Cancer

For many cancers, African Americans have higher incidence and mortality rates than European Americans; disparities exist for cancers of the bladder, breast, colon, endometrium, lung, ovary, pancreas, prostate, rectum, testes, and vagina, and for Hodgkin's lymphoma [73,74] (Table 2). Higher incidence and lower survival both contribute to some of those differences; for 2008-2012, African American males had a 12% higher overall cancer incidence and a 27% higher mortality rate than white men, whereas African American females had a 4% lower incidence rate but a 14% higher mortality rate than white women [74]. In many of the analyses, these differences in cancer rates were adjusted for a variety of potential confounding variables. Smoking, a major cause of cancer, does not account
for the disparities because smoking rates for African Americans and European Americans are similar [74].
__Table 2. Incidence and mortality rates for select cancers in the U.S. for males and females, 20082012 [74].))

* Age-adjusted cases/100,000/yr; ** Age-adjusted deaths/100,000/yr.

In single-country geographical ecological studies, solar UVB doses are inversely associated with mortality rates for many cancers among white people [75], and within the U.S. similar inverse associations are seen among both European Americans and African Americans [76-78]. Variables related to socioeconomic status can be hard to account for completely, especially in ecological studies. However, among male health professionals with similar education and occupation, African Americans with few risk factors for hypo- vitaminosis D had risks of cancer similar to those of white men; in contrast, African-American men with several risk factors for hypovitaminosis D had a 57% higher total cancer incidence and 127% higher cancer mortality rate [79]. Risk factors for hypovitaminosis D in this population included living in a region with low solar UVB doses, not spending much recreational time out of doors, and not taking vitamin D supplements. The excess risks were greater for digestive-tract cancers. The mechanisms by which vitamin D may reduce risk of cancer incidence and death include effects on cellular differentiation, proliferation, and apoptosis; anti-angiogenesis; and anti-metastasis [80], as well as anti-inflammatory [80,81] and immune-enhancing [82] mechanisms.
Colorectal cancer. Among various malignancies, low vitamin D status has been most consistently associated with colorectal cancer. In ecological analyses within the United States, colorectal cancer (CRC) mortality among European Americans has been lowest in southwestern states and highest in northeastern states, and lowest in the southern states and highest in the northern states for African Americans (data missing for many states) consistent with the pattern of solar UVB doses in summer [77,78,83]. In an analysis of race and 25(OHD) levels in relation to risk of death due to colorectal cancer [84], a significant two-fold increase in risk was seen among both non-Hispanic white and non-Hispanic black participants when comparing those with 25(OHD) levels less than 20 ng/mL to those with higher levels. Further, adjustment for vitamin levels accounted for almost half of the excess risk of colorectal cancer seen for black compared with white participants. In a recent systematic review and meta-analysis of 11 observational studies involving 7718 patients with CRC, overall survival was 32% greater when comparing high with low levels of 25(OH)D [85]. Thus, substantial evidence suggests a benefit for vitamin D in reducing CRC incidence and mortality.
Bladder and kidney cancers. In a meta-analysis of four prospective studies and one case-control study [86], the risk of urinary bladder cancer was 32% higher when comparing low versus high 25(OH)D level (risk ratio = 1.32 (95% confidence interval (CI), 1.15 to 1.89)). In a meta-analysis of two prospective cohort studies and seven nested case-control studies involving 130,609 participants who developed 1815 cases of kidney cancer, the highest 25(OH)D levels were associated with a significant 21% lower incidence (OR = 0.79, (95% CI, 0.69 to 0.91)) of kidney cancer [87].
Prostate cancer. In contrast to other cancers, higher 25(OH)D levels have been associated with a modestly higher risk of prostate cancer in prospective studies. A meta-analysis of 19 prospective cohort or nested case-control studies with a total of 35,583 participants and 12,786 prostate cancer cases found that higher 25(OH)D level was associated with increased prostate cancer relative risk = 1.15 (95% CI 1.02 to 1.06) [88]. On the other hand, a meta-analysis of six cohorts of 7648 patients with prostate cancer, for prostate cancer-specific mortality the hazard ratio for high vs. low 25(OH)D was 0.91 (95% CI: 0.880.95) for prediagnosis studies and 0.84 (95% CI: 0.58-1.21) for postdiagnosis serum levels [89]. In a case-control study, African-American men with a higher intake of vitamin D had a lower risk of total and aggressive prostate cancer; these associations were not seen in European men [90].
Breast cancer. In a meta-analysis of cohort studies, women with higher versus lower baseline serum levels of 25(OH)D had a barely significant 8% lower incidence of breast cancer [91]; the inverse association was limited to premenopausal women. However, in a pooled analysis of cohort studies with 10,353 cases of breast cancer, standardized serum levels of 25(OH)D were not associated with risk of breast cancer overall or by menopausal status. There was also no statistically significant difference by race (P for heterogeneity = 0.90). For the same increment in 25(OH)D levels, the RR was 0.98 (CI, 0.95 to 1.02) in whites (9,579 cases); 1.28 (CI, 0.99 to 1.65) in blacks (290 cases); and 1.13 (CI, 0.76 to 1.68) in Asians (275 cases) [92]. In a cohort of 59,000 African-American women, predicted serum 25(OH)D levels (based on sun exposure, dietary intake, adiposity, and other variables) were inversely associated with risk of breast cancer (1454 cases): risk was 23% higher for the lowest versus the highest quintile [93]. In a recent case-control study among black women, daylight hours spent outdoors per year was inversely associated with lower risk of breast cancer [94].
Total cancer: The VITAL Randomized Trial. In the large VITAL trial [95] participants were randomized to 2000 IU of vitamin D per day and followed for five years. Although vitamin D was interpreted to have no significant overall effect on total cancer incidence, the incidence among African Americans was reduced by 23% (HR = 0.77 (95% CI, 0.59 to 1.01, p = 0.06)). Further, after excluding the first two years of follow-up as part of the planned analysis, total cancer mortality was significantly (p <0.05) reduced by 25% (HR = 0.75 (95% CI, 0.59 to 0.96)) among all participants. Notably, the inclusion of participants with a relatively high baseline serum 25(OH)D level (mean = 31 ng/mL), many of whom also took supplementary vitamin D, plus the limited duration of follow-up, may have obscured benefits of vitamin D for cancer incidence. In a recent meta-analysis of ten RCTs including VITAL, no benefit of vitamin D supplementation was seen for cancer incidence (6537 cases) [96]. However, cancer mortality was reduced by 13% (95% CI, 4% to 21%) in the five available trials (1591 deaths). In another secondary analysis, there was a significant reduction in advanced cancers (metastatic or fatal) for those randomized to vitamin D compared with placebo [97].
Thus, the findings from randomized trials support vitamin D supplementation for reducing cancer mortality among all participants and cancer incidence among African Americans.

Diabetes Mellitus

In the United States, the age-standardized prevalence of total diabetes is approximately twice as high among non-Hispanic blacks and Hispanics compared to non-Hispanic whites [98]. In a meta-analysis of 28 trials with 3848 participants, vitamin D supplementation reduced HbA1c level by 0.48% (95% CI, 0.18 to 0.79), fasting plasma glucose level by 0.46 mmol/L (95% CI, 0.19 to 0.74), and homeostatic model assessment for insulin resistance (HOMA-IR) level by 0.39 (95% CI, 0.11 to 0.68), in comparison with the control group [99]. Supplemental vitamin D also improved insulin sensitivity in patients with initial low 25(OH)D levels [100].
Several RCTs, each reported as negative, have examined how vitamin D affects risk of diabetes among individuals with prediabetes [101,102]. In the Vitamin D and Type 2 Diabetes (D2d) Study among patients with prediabetes (25% of the 2423 participants were African American) [102], those randomized to vitamin D (4000 IU/d) had a nonsignificant 12% (-25 to +4%) lower progression to type 2 diabetes (T2DM) than those receiving placebo [102]. However, in a post hoc analysis among participants with a baseline 25(OH)D level of less than 12 ng/mL (103 participants), progression to diabetes was 62% lower with vitamin D verses placebo (95% CI, 20 to 0.82%). In two other randomized trials, modest and not statistically significant reductions in risk of T2DM were found with vitamin D supplementation [102,103]. If the results for those three randomized trials are combined, the overall reduction in risk is statistically significant (hazard ratio = 0.88; 95% CI, 0.78 to 0.99; p = 0.04, unpublished analysis).
Subsequently, an additional secondary analysis of the D2d trial was published [104]. The relationship between intra-trial 25(OH)D levels and incidence of T2DM was determined. The HR for T2DM for an increase of 10 ng/mL in intra-trial 25(OH)D level (n = 1074) was 0.75 (95% CI 0.68-0.82) among those assigned to vitamin D and 0.90 (0.80-1.02) among those assigned to placebo. The HRs for T2DM among participants treated with vitamin D who maintained intra-trial 25(OH)D levels of 40-50 (n = 319) and >50 ng/mL (n =430) were 0.48 (0.29-0.80) and 0.29 (0.17-0.50), respectively, compared with those who maintained a level of 20-30 ng/mL (n = 78). In a recent Mendelian randomization (MR) analysis, genetically predicted 25(OHD)D levels, and particularly alleles in genes involved in vitamin D synthesis) were inversely associated with incidence of type 2 diabetes [105].
Thus, the available evidence supports a modest overall benefit of vitamin D in reducing risk of T2DM [102] and possibly a substantial benefit among people with low serum 25(OH)D levels, such as African Americans.

Cardiovascular Disease

Inverse associations have been reported in studies of serum levels of 25(OH)D with risk of cardiovascular disease [106], including analyses specifically among African Americans [107-109]. However, no association was seen in MR studies [110] and in the large VITAL trial [95], including in participants with serum levels of 25(OH)D below 20 ng/mL and in African Americans. No association was also seen in a meta-analysis of vitamin D RCTs [111].

Alzheimer's Disease and Dementia and Cognitive Function

Multiple lines of evidence support a role of vitamin D in lowering risk of Alzheimer's disease (AD) [112]. In a meta-analysis of seven prospective studies and one retrospective cohort study (1953 cases of dementia and 1607 cases of AD), a serum level of 25(OH)D <10 ng/mL was associated with a 31% higher risk of dementia and a 33% higher risk of AD when compared with levels >20 ng/mL [113]. In one prospective study, 30% of participants were African American; higher baseline levels of 25(OH)D were associated with lower rates of cognitive decline but the numbers of were not large enough for race-specific analyses [114].
In MR analyses using the International Genomic of Alzheimer's Project (IGAP) dataset, risk of AD was found to be lower for individuals with genetic variants predicting higher levels of serum 25(OH)D compared to those without these variants [115]. In the most recent analysis using six such alleles (21,982 cases of Alzheimer's disease and 41,944 controls), the relative risk per allele was 0.62 (95% confidence interval 0.46 to 0.84) [115]. Together with the data based on serum levels of 25(OH)D, these findings provide substantial evidence that adequate vitamin D will reduce risk of dementia.

Multiple Sclerosis

In ecological studies, consistent with animal models [116], low solar UVB exposure is strongly associated with greater risk of multiple sclerosis (MS) [117] in whites, African Americans, and Hispanic Americans [118]. The inverse association between UVB exposure and MS also was seen in studies of individuals [119,120]. Solar UVB exposure in winter appears especially important.
In cohort studies, serum levels of 25(OH)D have been inversely associated with risk of MS [121]. In U.S. military recruits, levels greater than 40 ng/mL were associated with the lowest risk of MS, a level few African Americans attained [121]. In a Swedish study, 25(OH)D levels in the highest quintile were associated with a 32% lower incidence of MS [122]. Low levels of 25(OH)D in neonatal blood spots were strongly associated with MS later in life [123], supporting the importance of maternal vitamin D status during pregnancy. In a large cohort of women, use of vitamin D supplements greater than or equal to 400 IU/day was associated with lower risk of MS, but intake from diet, which rarely exceeds 400 IU/day, was not [124]. A cohort study conducted in southern California included a modest number of Black, Hispanic, and White participants with MS and matched controls. An inverse association between serum 25(OH)D level and incidence of MS was seen in Whites, but not among Blacks or Hispanics [118], but in all three groups a careful assessment of lifetime solar exposure was inversely associated with risk of MS. The authors suggested that something about solar exposure independent of vitamin D may be protective for MS, but an alternative explanation could be that their lifetime solar exposure assessment provided a better indication of long term vitamin D status (which would have been correlated with solar exposure over this period) than a single blood measurement collected in midlife.
A review of vitamin D supplementation in MS found little benefit even at high vitamin D doses [125]. The reasons for lack of benefit of vitamin D supplement suggested by the authors included the number of participants being too low, the length of the trial too short, baseline serum 25(OH)D levels too high, and other treatments being administered reducing the potential of vitamin D to help.
In a MR analysis of two large cohorts including 7391 cases of MS and 14,777 controls, a genetic risk score comprised of three alleles known to be associated with higher plasma 25(OH)D predicted levels was associated with lower risk of MS [126]. In the meta-analyses of these cohorts, the relative risk per allele was 0.85 (95% CI, 0.76 to 0.94, p = 0.003). This result, in combination with the other extensive observational study evidence, supports a protective role of adequate vitamin D intake for incidence of MS.

Acute Respiratory Tract Infections and COVID-19

Substantial evidence indicates that higher serum 25(OH)D levels can reduce the risk or severity of acute respiratory tract infections, possibly including COVID-19. Potential mechanisms include role of vitamin D in innate and acquired immunity [127,128].This relation was suggested by observations that the seasonal increase in influenza infections corresponds with lower solar UVB doses and 25(OH)D levels [129] and that in the 19181919 influenza pandemic the case-fatality rates were much lower in the southwestern U.S. states than in the northeastern states [130]. In a meta-analysis of 25 RCTs involving 10933 participants, vitamin D supplementation (daily or weekly) reduced risk of acute respiratory tract infections by 19% [131]. For participants with baseline 25(OH)D level <10 ng/mL, the reduction was 70%. In a post hoc analysis of an RCT conducted among 208 postmenopausal African-American women living in New York, supplementation with 1000 or 2000 IU/day of vitamin D3 compared to a placebo significantly reduced rates of influenza and colds [132].
Adequate vitamin D supplementation has also been hypothesized to decrease incidence and death from COVID-19; in addition to reducing viral replication, vitamin D may limit excess production of pro-inflammatory cytokines underlying the “cytokine storm” that damages the lungs and other organs [130,133]. Incidence and mortality of COVID have been far higher in African Americans than in European Americans [134]; after adjustment for age, African Americans are 4.5 times more likely to die from COVID-19 than European Americans [135]. Much of this could be due to more crowded housing, riskier jobs, dependence on public transportation, and higher prevalence of existing cardiometa- bolic conditions, but the high prevalence of vitamin D deficiency may also contribute.
Among patients with COVID-19, the disease resulting from SARS-CoV-2 infection followed by a dysregulated immune response, low levels of 25(OH)D at time of diagnosis have been associated with more severe illness [136-138]. Reverse causation cannot be excluded because serum 25(OH)D level decreases in response to acute inflammatory disease [139,140], but serum 25(OH)D levels have been associated with SARS-CoV-2 virus positivity using seasonally-adjusted 25(OH)D levels from the preceding 12 months [141,142].
The strong suggestion of benefits of vitamin D supplementation for preventing or treating COVID-19 has encouraged the initiation of supplementation trials [143]. In a non- randomized intervention study conducted in Spain among hospitalized patients hospitalized for COVID-19 [144], high doses of vitamin D (as 25(OH) D3) were administered in combination with standard care; only 1/50 required admission to the intensive care unit compared to 13/26 comparable control patients. An RCT conducted in India involving 40 SARS-CoV-2 positive patients with serum 25(OH)D with mean values near 9 ng/mL were randomized into high-dose vitamin D treatment (n = 16) and control (n = 24) groups [1451- Ten (63%) participants in the intervention group and five (21%) participants in the control arm (p < 0.02) became SARS-CoV-2 RNA negative. According to the registry of clinical trials [[146] as of 30 December 2020, there were at least 35 RCTs registered examining the role of vitamin D supplementation in prevention or treatment of COVID-19. In these trials, it will be important to distinguish among those with low versus adequate vitamin D status at baseline.

Asthma Exacerbations

A combined analysis of two RCTs conducted with pregnant women found that vitamin D supplementation (2400 IU/d and 4000 IU/d) reduced risk of asthma/recurrent wheeze from 0-3 years by 24% (aOR = 0.74 (95% CI, 0.57 to 0.96)) [147]. The effect was strongest for those with baseline 25(OH)D level >30 ng/mL (aOR = 0.54 (95% CI, 0.33 to 0.88)). A secondary analysis of the 4000 IU/d vitamin D RCT found that there was no difference with respect to race for African American vs. non-African American [148]. In a meta-analysis of individual participant data from seven RCTs with high-quality evidence, vitamin D supplementation reduced by 26% the risk of asthma exacerbation that required treatment with systemic corticosteroids [149]. The reduction was 67% for individuals with initial 25(OH)D level <10 ng/mL (92 participants). Thus, there is good evidence that raising serum 25(OH)D levels reduces risk of asthma or its exacerbation.

All-Cause Mortality

A comparison of death rates for African Americans with those of European Americans shows a large disparity for many diseases [150]. For example, the disparity in death rates from all causes for people aged 50 to 64 years is 45% higher in African American than in European Americans (Figure 3). Differences in multiple factors, such as hypertension, obesity, diet, income, education, and lower access to medical care, may contribute to some of those disparities, but they do not fully explain the differences [151-155].
In a meta-analysis (~29,000 subjects from five Northern European countries), serum levels of 25(OH)D below 32 ng/mL were associated with the highest mortality [156]. In another meta-analysis of 32 studies, mortality for those in the lowest (<9 ng/mL) was about double compared with those with the highest serum 25(OH)D level. The lowest mortality was reached near 40 ng/mL and plateaued above this level [157]. Most of those analyses accounted for potentially confounding variables such as adiposity, physical activity, and smoking, but some residual confounding could not be excluded.
More direct evidence for causality comes from a MR analysis documenting an association between genetically determined serum 25(OH)D levels and both total and cancer- specific mortality [110]. Although in a MR analysis from the UK Biobank genetically determined 25(OH)D level was not associated with all-cause mortality rate [158], that study was underpowered according to the authors, especially given that the association appears nonlinear.
A US cohort of 3075 adults aged 70-79 years of age was followed for 8.5 years [159]. Although the prevalence of vitamin D deficiency was much higher in Blacks than in Whites, lower baseline serum levels of 25(OH)D were similarly associated with higher mortality in both Black and White participants (Figure 4). Because of the large Black/White difference in vitamin D status, 25(OH)D levels below 30 ng/mL statistically accounted for 38% of mortality in Blacks and 11% in Whites. In a multivariate model without 25(OH)D levels, Blacks had 22% higher mortality than Whites, but after inclusion of 25(OH)D in the model the excess mortality in Blacks was only 9% and not statistically significant.
Similar findings were seen in a nested case-control analysis from a cohort of largely African-American participants, in which 1852 cohort members who died were matched to a similar number of participants who remained alive. Using baseline serum samples, the multivariate OR for death for those in lowest quartile compared with the highest quartile was 1.60 (95% confidence interval (CI): 1.20, 2.14, ptrend = 0.003) for African Americans and 2.11 (95% CI: 1.39, 3.21, ptrend < 0.001) for non-African Americans; the adjusted mortality rate became flat above approximately 30 ng/mL for both groups [160]. In the VITAL trial, no significant effect of vitamin D supplements on total mortality was seen in black or white participants, but the study was limited by duration and relatively high baseline levels [95].
Thus, there is good evidence from observational studies that all-cause mortality rate is inversely correlated with serum 25(OH)D concentrations up to about 30 to 40 ng/mL and then the association becomes flat.

Discussion

This review calls attention to the health-related consequences of low 25(OH)D levels for people with dark skin living at high northern latitudes, in both annual average and winter or summer [31,161]. Serum 25(OH)D levels are much lower among people with dark skin than among those with light skin living at similar latitudes. The prevalence of a serious deficiency value of 10 ng/mL (or less) is particularly high among African Americans. Regardless of skin color, low 25(OH)D levels are associated with higher incidence or poorer outcomes for many diseases. Evidence is particularly strong for several complications of pregnancy, multiple sclerosis, dementia, type 2 diabetes, colorectal cancer, total cancer mortality, and acute respiratory tract infections. For several of these diseases, causality is supported by either RCTs (such as for cancer mortality [95], diabetes mellitus [102], and acute respiratory tract infections [131]) or by the combination of prospective cohort and MR studies (such as for MS and dementia). Even if not all those relationships are ultimately determined to be causal, the consequences of vitamin D deficiency on the remaining diseases are important. On the basis of that evidence, vitamin D deficiency is highly likely to contribute to disparities in health status between people with dark and light skin at high latitudes. Hopefully, this review, by assembling the latest information on vitamin D for many health outcomes, will motivate physicians and patients to consider improving vitamin D status as an efficient way to improve health regardless of skin type.
Our study contrasts with the interpretations of several recent major RCTs on vitamin D supplementation [95,102] which reported no benefit of vitamin D supplementation. Although RCTs of vitamin D supplementation can be useful or definitive if a clear effect is seen, they also can be misinterpreted or misleading if no statistically significant effect is seen for various reasons, such as that the baseline and achieved 25(OH)D levels were either not measured or not considered in designing the trial [162,163]. Therefore, important benefits would be missed if many participants had levels high enough before randomization. For ethical or practical reasons, many RCTs do not focus on participants with vitamin D deficiency [95,102,164] who would be the people who would benefit most from supplementation. Also, some trials permit or encourage all participants to take additional vitamin D (400 to 800 IU/d), thereby reducing the risk of disease in the control group [95]. For some trial outcomes, especially cancer incidence, supplementation for long periods may be needed, but the effort is complicated by declining adherence. Our reasons for reaching a different conclusion include consideration of a broader literature, including important recent studies, and of secondary analyses for subpopulations, such as African Americans, most likely to benefit [165].
Observational cohort studies can circumvent some of those problems, but some residual confounding may be hard to exclude. Community-based observational studies in which participants take a vitamin D dose of their choice, have 25(OH)D levels measured semiannually, and report any changes in health status such as those conducted by Grass- rootsHealth.net, e.g., [166], can play a role. No single type of study will provide the best evidence for all hypotheses, and the greatest insights will come from a thoughtful combination of research strategies. Those studies should especially include people with dark skin, in particular African Americans.

Preventing Vitamin D Deficiency

Few foods, mainly fish and fish liver, have substantial amounts of vitamin D, which is primarily synthesized in the skin. Therefore, low 25(OH)D levels are largely determined by melanin levels and contemporary lifestyles (including getting little sun exposure by staying indoors, covering the body, and using sunscreen extensively) and excess body fat [167]. For people with dark skin, especially if living at northern latitudes and in winter, typical sun exposure will usually not be adequate to prevent deficiency. Notably, while leisure-time sun exposure contributes to serum levels of 25(OH)D in European Americans, it does so minimally in African Americans [168]. Vitamin D supplementation can effectively prevent deficiency. Fortifying milk with vitamin D has prevented rickets in children, but the amount of vitamin D (100 IU per 8 oz [240 mL]) would have only small effects on serum levels in adults. In addition, milk consumption has decreased over time and lactose intolerance is common, especially among African Americans [169]. Thus, intakes may need to be increased primarily by fortifying additional foods, including nondairy, or use of supplements; issues of dose and frequency of administration suggest that levels of at least 30 ng/mL would be a reasonable target. Notably, while solar UVB exposure is an important source of vitamin D, African Americans have high prevalence of 25(OH)D levels below 30 ng/mL in both summer (88%) and winter (93%), which contrasts for European Americans (61% in winter and 49% in summer) and Hispanics (86% in winter and 57% in summer) [161].
One strategy would be to screen routinely and to supplement people with low serum levels, but ideally a safe dose could be identified that yields near-optimal serum levels for almost everyone. A level of 20 ng/mL or higher was considered sufficient by an IOM committee in 2011 [36]; however, levels between 20 and 30 ng/mL have also been associated with lower risks of colorectal cancer [170], total mortality [157], dementia [113], multiple sclerosis [122] and bone mineral density [49,171].
Other researchers have suggested that 40 to 60 ng/mL is optimal based on results of small observational studies with participants taking high vitamin D3 doses [172-174]. Three-quarters of African Americans not already taking supplements have levels that do not ensure adequacy even by the IOM definition (20 ng/mL), and 96% have levels below 30 ng/mL. Notably, for African Americans living in Boston, 4000 IU/day was required to achieve serum levels of 30 ng/mL [175]. Similarly, among men with early prostate cancer, serum levels of 25(OH)D were much lower in African Americans compared with European Americans, but after supplementation of 4000 IU/day for one year, levels increased in both groups and were nearly identical [176]. In 2012, vitamin D supplements were used by only 12% of African Americans and 22% of European Americans [177]. Noting the be- tween-person variation in response to the same dose of vitamin D, some have suggested the desirability of monitoring indicators of biological function [178]. While this deserves consideration, it would add greatly to costs, and the specific variables to monitor are not clear at this time [179].
Vitamin D supplementation up to 4000 IU of vitamin D daily was considered to be safe by the 2011 IOM review. Further assurance comes from the trial using 4000 IU/day for 2.5 years [102]. An intake of 4000 IU/day has been used without adverse effects during pregnancy [61,67]. Higher intakes may also be safe [170,180] and warrant further study. At very high doses, such as in accidental exposures, vitamin D can produce death, neurological symptoms and serious damage (e.g., 1 million IU/day for several weeks, although the damage can sometimes be reversed [181]); at less extreme doses, a primary concern has been hypercalciuria and kidney stones [182], although any excess risk of kidney stones appears to be minimal when taking vitamin D supplements up to 4000 IU per day [183].

Conclusions

Together, ecological studies, prospective cohort studies based on blood levels, MR studies, and randomized trials provide moderate-to-strong evidence that low levels of 25(OH)D have many adverse health consequences. In addition, the fact that the vitamin D hormone, calcitriol, controls a considerable percentage of the human genome [1] indicates that it must be of huge general importance for health.
Much evidence is at present derived from studies of people of European descent. However, the benefits of supplementation for most health outcomes (other than skeletal effects) probably apply to all groups but are likely to be greatest for people with dark skin living at higher latitudes, such as African Americans, as well as most people in winter and those spending little time in the sun during summers. Many of the health disparities we discuss also have a basis in income inequality, poorer education and employment opportunities, poor housing, food insecurity, and other social inequalities; efforts to improve 25(OH)D levels will not lessen the need to address these factors but should improve health outcomes. While further research is needed to identify the optimal strategy for vitamin D supplementation and fortification, no reason exists to delay addressing vitamin D deficiency among populations with high prevalence of deficiency such as African Americans. The potential benefits promise to be large, and much evidence indicates that the risks of supplementation up to 4000 IU per day vitamin D are minimal.

References

1. 1. Ramagopalan, S.V.; Heger, A.; Berlanga, A.J.; Maugeri, N.J.; Lincoln, M.R.; Burrell, A.; Handunnetthi, L.; Handel, A.E.; Disanto, G.; Orton, S.M.; et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution. Genome Res. 2010, 20, 1352-1360, doi:10.1101/gr.107920.110.
2. Engelsen, O. The relationship between ultraviolet radiation exposure and vitamin D status. Nutrients 2010, 2, 482-495, doi:10.3390/nu2050482.
3. Jablonski, N.G.; Chaplin, G. Colloquium paper: Human skin pigmentation as an adaptation to UV radiation. Proc. Natl. Acad. Sci. USA 2010, 107 (Suppl. 2), 8962-8968, doi:10.1073/pnas.0914628107.
4. Weishaar, T.; Rajan, S.; Keller, B. Probability of Vitamin D Deficiency by Body Weight and Race/Ethnicity. J. Am. Board Fam. Med. 2016, 29, 226-232, doi:10.3122/jabfm.2016.02.150251.
5. Andersen, T.B.; Dalgaard, C.J.; Skovsgaaaard, C.V.; Selaya, P. Historical migration and contemporary health. Oxf. Econ. Pap. 2021, 1-27, doi:10.1093/oep/gpaa047.
6. Forrest, K.Y.; Stuhldreher, W.L. Prevalence and correlates of vitamin D deficiency in US adults. Nutr. Res. 2011, 31, 48-54, doi:10.1016/j.nutres.2010.12.001.
7. Williams, D.R.; Yan, Y.; Jackson, J.S.; Anderson, N.B. Racial Differences in Physical and Mental Health: Socio-economic Status, Stress and Discrimination. J. Health Psychol. 1997, 2, 335-351, doi:10.1177/135910539700200305.
8. Williams, D.R.; Collins, C. Racial residential segregation: A fundamental cause of racial disparities in health. Public Health Rep. 2001, 116, 404-416, doi:10.1093/phr/116.5.404.
9. Sampson, R.J.; Raudenbush, S.W.; Earls, F. Neighborhoods and violent crime: A multilevel study of collective efficacy. Science 1997, 277, 918-924, doi:10.1126/science.277.5328.918.
10. Moukayed, M.; Grant, W.B. The roles of UVB and vitamin D in reducing risk of cancer incidence and mortality: A review of the epidemiology, clinical trials, and mechanisms. Rev. Endocr. Metab. Disord. 2017, 18, 167-182, doi:10.1007/s11154-017-9415-2.
11. Holick, M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357, 266-281, doi:10.1056/NEJMra070553.
12. Bikle, D.D. Vitamin D and cancer: The promise not yet fulfilled. Endocrine 2014, 46, 29-38, doi:10.1007/s12020-013-0146-1.
13. Dai, Q.; Zhu, X.; Manson, J.E.; Song, Y.; Li, X.; Franke, A.A.; Costello, R.B.; Rosanoff, A.; Nian, H.; Fan, L.; et al. Magnesium status and supplementation influence vitamin D status and metabolism: Results from a randomized trial. Am. J. Clin. Nutr. 2018, 108, 1249-1258, doi:10.1093/ajcn/nqy274.
14. Carlberg, C. Vitamin D Genomics: From In Vitro to In Vivo. Front. Endocrinol. 2018, 9, 250, doi:10.3389/fendo.2018.00250.
15. Shirvani, A.; Kalajian, T.A.; Song, A.; Holick, M.F. Disassociation of Vitamin D's Calcemic Activity and Non-calcemic Genomic Activity and Individual Responsiveness: A Randomized Controlled Double-Blind Clinical Trial. Sci. Rep. 2019, 9, 17685, doi:10.1038/s41598-019-53864-1.
16. Pike, J.W.; Christakos, S. Biology and Mechanisms of Action of the Vitamin D Hormone. Endocrinol. Metab. Clin. North Am. 2017, 46, 815-843, doi:10.1016/j.ecl.2017.07.001.
17. Patrick, R.P.; Ames, B.N. Vitamin D hormone regulates serotonin synthesis. Part 1: Relevance for autism. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2014, 28, 2398-2413, doi:10.1096/fj.13-246546.
18. Patrick, R.P.; Ames, B.N. Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: Relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. FASEB J. Off. Publ. Fed. Am. Soc. Ex~p. Biol. 2015, 29, 2207-2222, doi:10.1096/fj.14-268342.
19. Ames, B.N. Prolonging healthy aging: Longevity vitamins and proteins. Proc. Natl. Acad. Sci. USA 2018, 115, 10836-10844, doi:10.1073/pnas.1809045115.
20. Jablonski, N.G.; Chaplin, G. The evolution of skin pigmentation and hair texture in people of African ancestry. Dermatol. Clin. 2014,32, 113-121, doi:10.1016/j.det.2013.11.003.
21. Jablonski, N.G.; Chaplin, G. The roles of vitamin D and cutaneous vitamin D production in human evolution and health. Int. J. Paleopathol. 2018, 23, 54-59, doi:10.1016/j.ijpp.2018.01.005.
22. Chaplin, G. Geographic distribution of environmental factors influencing human skin coloration. Am. J. Phys. Anthro-pol. 2004, 125, 292-302, doi:10.1002/ajpa.10263.
23. Clemens, T.L.; Adams, J.S.; Henderson, S.L.; Holick, M.F. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982, 1, 74-76, doi:10.1016/s0140-6736(82)90214-8.
24. Matsuoka, L.Y.; Wortsman, J.; Haddad, J.G.; Kolm, P.; Hollis, B.W. Racial pigmentation and the cutaneous synthesis of vitamin D. Arch. Dermatol. 1991, 127, 536-538.
25. Adhikari, K.; Mendoza-Revilla, J.; Sohail, A.; Fuentes-Guajardo, M.; Lampert, J.; Chacon-Duque, J.C.; Hurtado, M.; Villegas, V.; Granja, V.; Acuna-Alonzo, V.; et al. A GWAS in Latin Americans highlights the convergent evolution of lighter skin pigmentation in Eurasia. Nat. Commun. 2019, 10, 358, doi:10.1038/s41467-018-08147-0.
26. Campbell, P.A.; Young, M.W.; Lee, R.C. Vitamin D Clinical Pharmacology: Relevance to COVID-19 Pathogenesis. J. Natl. Med. Assoc. 2020, doi:10.1016/j.jnma.2020.09.152.
27. Hanel, A.; Carlberg, C. Skin colour and vitamin D: An update. Exp. Dermatol. 2020, 29, 864-875, doi:10.1111/exd.14142.
28. Luxwolda, M.F.; Kuipers, R.S.; Kema, I.P.; Dijck-Brouwer, D.A.; Muskiet, F.A. Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/l. Br. J. Nutr. 2012, 108, 1557-1561, doi:10.1017/S0007114511007161.
29. Luxwolda, M.F.; Kuipers, R.S.; Kema, I.P.; van der Veer, E.; Dijck-Brouwer, D.A.; Muskiet, F.A. Vitamin D status indicators in indigenous populations in East Africa. Eur. J. Nutr. 2013, 52, 1115-1125, doi:10.1007/s00394-012-0421-6.
30. Chiang, D.; Kramer, H.; Luke, A.; Cooper, R.; Aloia, J.; Bovet, P.; Plange-Rhule, J.; Forrester, T.; Lambert, V.; Camacho, P.; et al. 25-Hydroxyvitamin D and blood pressure: A plateau effect in adults with African ancestry living at different latitudes. J. Hypertens. 2017, 35, 968-974, doi:10.1097/HJH.0000000000001263.
31. Ginde, A.A.; Liu, M.C.; Camargo, C.A., Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch. Intern. Med. 2009, 169, 626-632, doi:10.1001/archinternmed.2008.604.
32. Kramer, H.; Camacho, P.; Aloia, J.; Luke, A.; Bovet, P.; Rhule, J.P.; Forrester, T.; Lambert, V.; Harders, R.; Dugas, L.; et al. Association between 25-Hydroxyvitamin D and Intact Parathyroid Hormone Levels across Latitude among Adults with African Ancestry. Endocr. Pr. 2016, 22, 911-919, doi:10.4158/EP151079.OR.
33. Enechukwu, N.; Cockburn, M.; Ogun, G.; Ezejiofor, O.I.; George, A.; Ogunbiyi, A. Higher vitamin D levels in Nigerian albinos compared with pigmented controls. Int. J. Dermatol. 2019, 58, 1148-1152, doi:10.1111/ijd.14611.
34. Chawla, D.; Daniels, J.L.; Benjamin-Neelon, S.E.; Fuemmeler, B.F.; Hoyo, C.; Buckley, J.P. Racial and ethnic differences in predictors of vitamin D among pregnant women in south-eastern USA. J. Nutr. Sci. 2019, 8, e8, doi:10.1017/jns.2019.4.
35. Liu, X.; Baylin, A.; Levy, P.D. Vitamin D deficiency and insufficiency among US adults: Prevalence, predictors and clinical implications. Br. J. Nutr. 2018, 119, 928-936, doi:10.1017/S0007114518000491.
36. Ross, A.C.; Manson, J.E.; Abrams, S.A.; Aloia, J.F.; Brannon, P.M.; Clinton, S.K.; Durazo-Arvizu, R.A.; Gallagher, J.C.; Gallo, R.L.; Jones, G.; et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J. Clin. Endocrinol. Metab. 2011, 96, 53-58, doi:10.1210/jc.2010-2704.
37. Arabi, A.; El Rassi, R.; El-Hajj Fuleihan, G. Hypovitaminosis D in developing countries-prevalence, risk factors and outcomes. Nat. Rev. Endocrinol. 2010, 6, 550-561, doi:10.1038/nrendo.2010.146.
38. Zhang, W.; Stoecklin, E.; Eggersdorfer, M. A glimpse of vitamin D status in Mainland China. Nutrition 2013, 29, 953-957, doi:10.1016/j.nut.2013.01.010.
39. Gupta, A. Vitamin D deficiency in India: Prevalence, causalities and interventions. Nutrients 2014, 6, 729-775, doi:10.3390/nu6020729.
40. Vatandost, S.; Jahani, M.; Afshari, A.; Amiri, M.R.; Heidarimoghadam, R.; Mohammadi, Y. Prevalence of vitamin D deficiency in Iran: A systematic review and meta-analysis. Nutr. Health 2018, 260106018802968, doi:10.1177/0260106018802968.
41. Pilz, S.; Marz, W.; Cashman, K.D.; Kiely, M.E.; Whiting, S.J.; Holick, M.F.; Grant, W.B.; Pludowski, P.; Hiligsmann, M.; Trummer, C.; et al. Rationale and Plan for Vitamin D Food Fortification: A Review and Guidance Paper. Front. Endocrinol. 2018, 9, 373, doi:10.3389/fendo.2018.00373.
42. Grant, W.B. Effect of follow-up time on the relation between prediagnostic serum 25-hydroxyvitamin D and all-cause mortality rate. Dermatoendocrinol 2012, 4, 198-202, doi:10.4161/derm.20514.
43. Bailie, G.R.; Johnson, C.A. Comparative review of the pharmacokinetics of vitamin D analogues. Semin. Dial. 2002, 15, 352-357, doi:10.1046/j.1525-139x.2002.00086.x.
44. Peiris, A.N.; Youssef, D.; Grant, W.B. Secondary hyperparathyroidism: Benign bystander or culpable contributor to adverse health outcomes? South Med. J. 2012, 105, 36-42, doi:10.1097/SMJ.0b013e31823c4155.
45. Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M.; Endocrine, S. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96, 1911-1930, doi:10.1210/jc.2011-0385.
46. Bischoff-Ferrari, H.A.; Dietrich, T.; Orav, E.J.; Dawson-Hughes, B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: A population-based study of younger and older adults. Am. J. Med. 2004, 116, 634-639, doi:10.1016/j.amjmed.2003.12.029.
47. Bell, N.H. Bone and mineral metabolism in African Americans. Trends Endocrinol. Metab. Tem 1997, 8, 240-245.
48. Aloia, J.F. African Americans, 25-hydroxyvitamin D, and osteoporosis: A paradox. Am. J. Clin. Nutr. 2008, 88, 545S-550S, doi:10.1093/ajcn/88.2.545S.
49. Gutierrez, O.M.; Farwell, W.R.; Kermah, D.; Taylor, E.N. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteo-poros. Int. 2011, 22, 17451753, doi:10.1007/s00198-010-1383-2.
50. Redmond, J.; Palla, L.; Yan, L.; Jarjou, L.M.; Prentice, A.; Schoenmakers, I. Ethnic differences in urinary calcium and phosphate excretion between Gambian and British older adults. Osteo-poros Int 2015, 26, 1125-1135, doi:10.1007/s00198-014-2926-8.
51. Vieth, R. Weaker bones and white skin as adaptions to improve anthropological "fitness" for northern environments. Osteoporos. Int. 2020, 31, 617-624, doi:10.1007/s00198-019-05167-4.
52. Powe, C.E.; Evans, M.K.; Wenger, J.; Zonderman, A.B.; Berg, A.H.; Nalls, M.; Tamez, H.; Zhang, D.; Bhan, I.; Karumanchi, S.A.; et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N.Engl. J. Med. 2013, 369, 19912000, doi:10.1056/NEJMoa1306357.
53. Hollis, B.W.; Bikle, D.D. Vitamin D-binding protein and vitamin D in blacks and whites. N.Engl. J. Med. 2014, 370, 879-880, doi:10.1056/NEJMc1315850.
54. Martin, J.A.; Hamilton, B.E.; Osterman, M.J.K.; Driscoll, A.K.; Drake, P. Births: Final Data for 2016. Natl. Vital Stat. Rep. Cent. Dis. Control Prev. Natl. Cent. Health Stat. Natl. Vital Stat. Syst. 2018, 67, 1-55.
55. Tangel, V.; White, R.S.; Nachamie, A.S.; Pick, J.S. Racial and Ethnic Disparities in Maternal Outcomes and the Disadvantage of Peripartum Black Women: A Multistate Analysis, 2007-2014. Am. J. Perinatol. 2018, doi:10.1055/s-0038-1675207.
56. Gyamfi-Bannerman, C.; Pandita, A.; Miller, E.C.; Boehme, A.K.; Wright, J.D.; Siddiq, Z.; D'Alton, M.E.; Friedman, A.M. Preeclampsia outcomes at delivery and race. J. Matern. Fetal Neonatal Med. 2019, 1-8, doi:10.1080/14767058.2019.1581522.
57. Bediako, P.T.; BeLue, R.; Hillemeier, M.M. A Comparison of Birth Outcomes Among Black, Hispanic, and Black Hispanic Women. J. Racial Ethn. Health Disparities 2015, 2, 573-582, doi:10.1007/s40615-015-0110-2.
58. Johnson, D.D.; Wagner, C.L.; Hulsey, T.C.; McNeil, R.B.; Ebeling, M.; Hollis, B.W. Vitamin D deficiency and insufficiency is common during pregnancy. Am. J. Perinato/. 2011, 28, 7-12, doi:10.1055/s-0030-1262505.
59. Luque-Fernandez, M.A.; Gelaye, B.; VanderWeele, T.; Ferre, C.; Siega-Riz, A.M.; Holzman, C.; Enquobahrie, D.A.; Dole, N.; Williams, M.A. Seasonal variation of 25-hydroxyvitamin D among non-Hispanic black and white pregnant women from three US pregnancy cohorts. Paediatr. Perinat. Epidemio/. 2014, 28, 166-176, doi:10.1111/ppe.12103.
60. Tian, Y.; Holzman, C.; Siega-Riz, A.M.; Williams, M.A.; Dole, N.; Enquobahrie, D.A.; Ferre, C.D. Maternal Serum 25- Hydroxyvitamin D Concentrations during Pregnancy and Infant Birthweight for Gestational Age: A Three-Cohort Study. Paediatr. Perinat. Epidemiol. 2016, 30, 124-133, doi:10.1111/ppe.12262.
61. Hollis, B.W.; Johnson, D.; Hulsey, T.C.; Ebeling, M.; Wagner, C.L. Vitamin D supplementation during pregnancy: Double-blind, randomized clinical trial of safety and effectiveness. J. Bone Miner. Res. : Off. J. Am. Soc. Bone Miner. Res. 2011, 26, 2341-2357, doi:10.1002/jbmr.463.
62. Liu, N.Q.; Hewison, M. Vitamin D, the placenta and pregnancy. Arch. Biochem. Biophys. 2012, 523, 37-47, doi:10.1016/j.abb.2011.11.018.
63. Fogacci, S.; Fogacci, F.; Banach, M.; Michos, E.D.; Hernandez, A.V.; Lip, G.Y.H.; Blaha, M.J.; Toth, P.P.; Borghi, C.; Cicero, A.F.G.; et al. Vitamin D supplementation and incident preeclampsia: A systematic review and meta-analysis of randomized clinical trials. Clin. Nutr. 2020, 39, 1742-1752, doi:10.1016/j.clnu.2019.08.015.
64. Bi, W.G.; Nuyt, A.M.; Weiler, H.; Leduc, L.; Santamaria, C.; Wei, S.Q. Association Between Vitamin D Supplementation During Pregnancy and Offspring Growth, Morbidity, and Mortality: A Systematic Review and Meta-analysis. JAMA Pediatr. 2018, 172, 635-645, doi:10.1001/jamapediatrics.2018.0302.
65. Seto, T.L.; Tabangin, M.E.; Langdon, G.; Mangeot, C.; Dawodu, A.; Steinhoff, M.; Narendran, V. Racial disparities in cord blood vitamin D levels and its association with small-for-gestational-age infants. J. Perinatol. : Off. J. Calif. Perinat. Assoc. 2016, 36, 623628, doi:10.1038/jp.2016.64.
66. Zhou, S.S.; Tao, Y.H.; Huang, K.; Zhu, B.B.; Tao, F.B. Vitamin D and risk of preterm birth: Up-to-date meta-analysis of randomized controlled trials and observational studies. J. Obs. Gynaecol. Res. 2017, 43, 247-256, doi:10.1111/jog.13239.
67. McDonnell, S.L.; Baggerly, K.A.; Baggerly, C.A.; Aliano, J.L.; French, C.B.; Baggerly, L.L.; Ebeling, M.D.; Rittenberg, C.S.; Goodier, C.G.; Mateus Nino, J.F.; et al. Maternal 25(OH)D concentrations >40 ng/mL associated with 60% lower preterm birth risk among general obstetrical patients at an urban medical center. PLoS ONE 2017, 12, e0180483, doi:10.1371/journal.pone.0180483.
68. Cannell, J.J. Autism and vitamin D. Med Hypotheses 2008, 70, 750-759, doi:10.1016/j.mehy.2007.08.016.
69. Garcia-Serna, A.M.; Morales, E. Neurodevelopmental effects of prenatal vitamin D in humans: Systematic review and metaanalysis. Mol. Psychiatry 2020, 25, 2468-2481, doi:10.1038/s41380-019-0357-9.
70. Wagner, C.L.; Hollis, B.W. The Implications of Vitamin D Status During Pregnancy on Mother and her Developing Child. Front. Endocrinol. 2018, 9, 500, doi:10.3389/fendo.2018.00500.
71. Merewood, A.; Mehta, S.D.; Chen, T.C.; Bauchner, H.; Holick, M.F. Association between vitamin D deficiency and primary cesarean section. J. Clin. Endocrinol. Metab. 2009, 94, 940-945, doi:10.1210/jc.2008-1217.
72. Rostami, M.; Tehrani, F.R.; Simbar, M.; Bidhendi Yarandi, R.; Minooee, S.; Hollis, B.W.; Hosseinpanah, F. Effectiveness of Prenatal Vitamin D Deficiency Screening and Treatment Program: A Stratified Randomized Field Trial. J. Clin. Endocrinol. Metab. 2018, 103, 2936-2948, doi:10.1210/jc.2018-00109.
73. Grant, W.B.; Peiris, A.N. Differences in vitamin D status may account for unexplained disparities in cancer survival rates between African and white Americans. Dermatoendocrinol 2012, 4, 85-94, doi:10.4161/derm.19667.
74. DeSantis, C.E.; Siegel, R.L.; Sauer, A.G.; Miller, K.D.; Fedewa, S.A.; Alcaraz, K.I.; Jemal, A. Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA: A Cancer J. Clin. 2016, 66, 290-308, doi:10.3322/caac.21340.
75. Moukayed, M.; Grant, W.B. Molecular link between vitamin D and cancer prevention. Nutrients 2013, 5, 3993^021, doi:10.3390/nu5103993.
76. Grant, W.B. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94, 1867-1875, doi:10.1002/cncr.10427.
77. Grant, W.B.; Garland, C.F. The association of solar ultraviolet B (UVB) with reducing risk of cancer: Multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates. Anticancer. Res. 2006, 26, 2687-2699.
78. Grant, W.B. Lower vitamin-D production from solar ultraviolet-B irradiance may explain some differences in cancer survival rates. J. Natl. Med. Assoc. 2006, 98, 357-364.
79. Giovannucci, E.; Liu, Y.; Willett, W.C. Cancer incidence and mortality and vitamin D in black and white male health professionals. Cancer Epidemiol. Biomark. Prev. 2006, 15, 2467-2472, doi:10.1158/1055-9965.EPI-06-0357.
80. Krishnan, A.V.; Feldman, D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu. Rev. Pharm. Toxicol. 2011, 51, 311-336, doi:10.1146/annurev-pharmtox-010510-100611.
81. Christakos, S.; Dhawan, P.; Verstuyf, A.; Verlinden, L.; Carmeliet, G. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol. Rev. 2016, 96, 365-408, doi:10.1152/physrev.00014.2015.
82. Song, M.; Nishihara, R.; Wang, M.; Chan, A.T.; Qian, Z.R.; Inamura, K.; Zhang, X.; Ng, K.; Kim, S.A.; Mima, K.; et al. Plasma 25- hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut 2016, 65, 296-304, doi:10.1136/gutjnl- 2014-308852.
83. Garland, C.F.; Garland, F.C. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int. J. Epidemiol. 1980, 9, 227-231.
84. Fiscella, K.; Winters, P.; Tancredi, D.; Hendren, S.; Franks, P. Racial disparity in death from colorectal cancer: Does vitamin D deficiency contribute? Cancer 2011, 117, 1061-1069, doi:10.1002/cncr.25647.
85. Maalmi, H.; Walter, V.; Jansen, L.; Boakye, D.; Schottker, B.; Hoffmeister, M.; Brenner, H. Association between Blood 25- Hydroxyvitamin D Levels and Survival in Colorectal Cancer Patients: An Updated Systematic Review and Meta-Analysis. Nutrients 2018, 10, 896, doi:10.3390/nu10070896.
86. Zhang, H.; Zhang, H.; Wen, X.; Zhang, Y.; Wei, X.; Liu, T. Vitamin D Deficiency and Increased Risk of Bladder Carcinoma: A Meta-Analysis. Cell Physiol. Biochem. 2015, 37, 1686-1692, doi:10.1159/000438534.
87. Lin, G.; Ning, L.; Gu, D.; Li, S.; Yu, Z.; Long, Q.; Hou, L.N.; Tan, W.L. Examining the association of circulating 25- hydroxyvitamin D with kidney cancer risk: A meta-analysis. Int. J. Clin. Ex-p. Med. 2015, 8, 20499-20507.
88. Gao, J.; Wei, W.; Wang, G.; Zhou, H.; Fu, Y.; Liu, N. Circulating vitamin D concentration and risk of prostate cancer: A dose- response meta-analysis of prospective studies. Clin. Risk Manag. 2018, 14, 95-104, doi:10.2147/TCRM.S149325.
89. Song, Z.Y.; Yao, Q.; Zhuo, Z.; Ma, Z.; Chen, G. Circulating vitamin D level and mortality in prostate cancer patients: A dose- response meta-analysis. Endocr. Connect 2018, 7, R294-R303, doi:10.1530/EC-18-0283.
90. Batai, K.; Murphy, A.B.; Ruden, M.; Newsome, J.; Shah, E.; Dixon, M.A.; Jacobs, E.T.; Hollowell, C.M.; Ahaghotu, C.; Kittles, R.A. Race and BMI modify associations of calcium and vitamin D intake with prostate cancer. BMC Cancer 2017, 17, 64, doi:10.1186/s12885-017-3060-8.
91. Estebanez, N.; Gomez-Acebo, I.; Palazuelos, C.; Llorca, J.; Dierssen-Sotos, T. Vitamin D exposure and Risk of Breast Cancer: A meta-analysis. Sci. Rep. 2018, 8, 9039, doi:10.1038/s41598-018-27297-1.
92. Visvanathan, K.; Mondul, A.; Zeleniuch-Jacquotte, A.; Mukhtar, T.K.; Smith-Warner, S.A.; Ziegler, R.G. A pooled analysis of 17 cohorts [abstract]. In Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium, 9-13 December 2014, San Antonio, TX, USA.
93. Palmer, J.R.; Gerlovin, H.; Bethea, T.N.; Bertrand, K.A.; Holick, M.F.; Ruiz-Narvaez, E.N.; Wise, L.A.; Haddad, S.A.; Adams- Campbell, L.L.; Kaufman, H.W.; et al. Predicted 25-hydroxyvitamin D in relation to incidence of breast cancer in a large cohort of African American women. Breast Cancer Res. BCR 2016, 18, 86, doi:10.1186/s13058-016-0745-x.
94. Qin, B.; Xu, B.; Ji, N.; Yao, S.; Pawlish, K.; Llanos, A.A.M.; Lin, Y.; Demissie, K.; Ambrosone, C.B.; Hong, C.C.; et al. Intake of vitamin D and calcium, sun exposure, and risk of breast cancer subtypes among black women. Am. J. Clin. Nutr. 2020, 111, 396405, doi:10.1093/ajcn/nqz302.
95. Manson, J.E.; Cook, N.R.; Lee, I.M.; Christen, W.; Bassuk, S.S.; Mora, S.; Gibson, H.; Gordon, D.; Copeland, T.; D'Agostino, D.; et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N.Engl. J. Med. 2019, 380, 33-44, doi:10.1056/NEJMoa1809944.
96. Keum, N.; Lee, D.H.; Greenwood, D.C.; Manson, J.E.; Giovannucci, E. Vitamin D supplementation and total cancer incidence and mortality: A meta-analysis of randomized controlled trials. Ann. Oncol. 2019, 30, 733-743, doi:10.1093/annonc/mdz059.
97. Chandler, P.D.; Chen, W.Y.; Ajala, O.N.; Hazra, A.; Cook, N.; Bubes, V.; Lee, I.M.; Giovannucci, E.L.; Willett, W.; Buring, J.E.; et al. Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial. JAMA Netw. Open 2020, 3, e2025850, doi:10.1001/jamanetworkopen.2020.25850.
98. Menke, A.; Casagrande, S.; Geiss, L.; Cowie, C.C. Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012. JAMA 2015, 314, 1021-1029, doi:10.1001/jama.2015.10029.
99. Mirhosseini, N.; Vatanparast, H.; Mazidi, M.; Kimball, S.M. Vitamin D Supplementation, Glycemic Control, and Insulin Resistance in Prediabetics: A Meta-Analysis. J. Endocr. Soc. 2018, 2, 687-709, doi:10.1210/js.2017-00472.
100. Niroomand, M.; Fotouhi, A.; Irannejad, N.; Hosseinpanah, F. Does high-dose vitamin D supplementation impact insulin resistance and risk of development of diabetes in patients with pre-diabetes? A double-blind randomized clinical trial. Diabetes Res. Clin. Pract. 2019, 148, 1-9, doi:10.1016/j.diabres.2018.12.008.
101. Kawahara, T. Eldecalcitol, a Vitamin D Analog, for Diabetes Prevention in Impaired Glucose Tolerance (DPVD Study). Diabetes 2018, 67(Suppl. 1), doi:10.2337/db18-120-LB.
102. Pittas, A.G.; Dawson-Hughes, B.; Sheehan, P.; Ware, J.H.; Knowler, W.C.; Aroda, V.R.; Brodsky, I.; Ceglia, L.; Chadha, C.; Chatterjee, R.; et al. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N.Engl. J. Med. 2019, doi:10.1056/NEJMoa1900906.
103. Jorde, R.; Sollid, S.T.; Svartberg, J.; Schirmer, H.; Joakimsen, R.M.; Njolstad, I.; Fuskevag, O.M.; Figenschau, Y.; Hutchinson, M.Y. Vitamin D 20,000 IU per Week for Five Years Does Not Prevent Progression From Prediabetes to Diabetes. J. Clin. Endocrinol. Metab. 2016, 101, 1647-1655, doi:10.1210/jc.2015-4013.
104. Dawson-Hughes, B.; Staten, M.A.; Knowler, W.C.; Nelson, J.; Vickery, E.M.; LeBlanc, E.S.; Neff, L.M.; Park, J.; Pittas, A.G.; Investigators, D.d.R.G. Intratrial Exposure to Vitamin D and New-Onset Diabetes Among Adults With Prediabetes: A Secondary Analysis From the Vitamin D and Type 2 Diabetes (D2d) Study. Diabetes Care 2020, doi:10.2337/dc20-1765.
105. Xu, Y.; Zhou, Y.; Liu, J.; Wang, C.; Qu, Z.; Wei, Z.; Zhou, D. Genetically increased circulating 25(OH)D level reduces the risk of type 2 diabetes in subjects with deficiency of vitamin D: A large-scale Mendelian randomization study. Medicine 2020, 19, e23672, doi:10.1097/MD.0000000000023672.
106. Gholami, F.; Moradi, G.; Zareei, B.; Rasouli, M.A.; Nikkhoo, B.; Roshani, D.; Ghaderi, E. The association between circulating 25- hydroxyvitamin D and cardiovascular diseases: A meta-analysis of prospective cohort studies. BMC Cardiovasc. Disord. 2019, 19, 248, doi:10.1186/s12872-019-1236-7.
107. Schneider, A.L.; Lutsey, P.L.; Selvin, E.; Mosley, T.H.; Sharrett, A.R.; Carson, K.A.; Post, W.S.; Pankow, J.S.; Folsom, A.R.; Gottesman, R.F.; et al. Vitamin D, vitamin D binding protein gene polymorphisms, race and risk of incident stroke: The Atherosclerosis Risk in Communities (ARIC) study. Eur. J. Neurol. 2015, 22, 1220-1227, doi:10.1111/ene.12731.
108. Judd, S.E.; Morgan, C.J.; Panwar, B.; Howard, V.J.; Wadley, V.G.; Jenny, N.S.; Kissela, B.M.; Gutierrez, O.M. Vitamin D deficiency and incident stroke risk in community-living black and white adults. Int. J. Stroke 2016, 11, 93-102, doi:10.1177/1747493015607515.
109. Paul, S.; Judd, S.E.; Howard, V.J.; Safford, M.S.; Gutierrez, O.M. Association of 25-hydroxyvitamin D with incident coronary heart disease in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Am. Heart J. 2019, 217, 140-147, doi:10.1016/j.ahj.2019.08.011.
110. Afzal, S.; Brondum-Jacobsen, P.; Bojesen, S.E.; Nordestgaard, B.G. Genetically low vitamin D concentrations and increased mortality: Mendelian randomisation analysis in three large cohorts. BMJ 2014, 349, g6330, doi:10.1136/bmj.g6330.
111. Orkaby, A.R.; Djousse, L.; Manson, J.E. Vitamin D supplements and prevention of cardiovascular disease. Curr. 〇-pin. Cardiol. 2019, 34, 700-705, doi:10.1097/HCO.0000000000000675.
112. Larsson, S.C.; Traylor, M.; Markus, H.S.; Michaelsson, K. Serum Parathyroid Hormone, 25-Hydroxyvitamin D, and Risk of Alzheimer's Disease: A Mendelian Randomization Study. Nutrients 2018, 10, 1501, doi:10.3390/nu10091243.
113. Jayedi, A.; Rashidy-Pour, A.; Shab-Bidar, S. Vitamin D status and risk of dementia and Alzheimer's disease: A meta-analysis of dose-response. Nutr. Neurosci. 2019, 22, 750-759, doi:10.1080/1028415X.2018.1436639.
114. Miller, J.W.; Harvey, D.J.; Beckett, L.A.; Green, R.; Farias, S.T.; Reed, B.R.; Olichney, J.M.; Mungas, D.M.; DeCarli, C. Vitamin D Status and Rates of Cognitive Decline in a Multiethnic Cohort of Older Adults. JAMA Neurol. 2015, 72, 1295-1303, doi:10.1001/jamaneurol.2015.2115.
115. Wang, L.; Qiao, Y.; Zhang, H.; Zhang, Y.; Hua, J.; Jin, S.; Liu, G. Circulating Vitamin D Levels and Alzheimer's Disease: A Mendelian Randomization Study in the IGAP and UK Biobank. J. Alzheimers Dis. 2020, 73, 609-618, doi:10.3233/JAD-190713.
116. Irving, A.A.; Marling, S.J.; Seeman, J.; Plum, L.A.; DeLuca, H.F. UV light suppression of EAE (a mouse model of multiple sclerosis) is independent of vitamin D and its receptor. Proc. Natl. Acad. Sci. USA 2019, 116, 22552-22555, doi:10.1073/pnas.1913294116.
117. Orton, S.M.; Wald, L.; Confavreux, C.; Vukusic, S.; Krohn, J.P.; Ramagopalan, S.V.; Herrera, B.M.; Sadovnick, A.D.; Ebers, G.C. Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology 2011, 76, 425-431, doi:10.1212/WNL.0b013e31820a0a9f.
118. Langer-Gould, A.; Lucas, R.; Xiang, A.H.; Chen, L.H.; Wu, J.; Gonzalez, E.; Haraszti, S.; Smith, J.B.; Quach, H.; Barcellos, L.F. MS Sunshine Study: Sun Exposure But Not Vitamin D Is Associated with Multiple Sclerosis Risk in Blacks and Hispanics. Nutrients 2018, 10, 268, doi:10.3390/nu10030268.
119. Gallagher, L.G.; Ilango, S.; Wundes, A.; Stobbe, G.A.; Turk, K.W.; Franklin, G.M.; Linet, M.S.; Freedman, D.M.; Alexander, B.H.; Checkoway, H. Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in the US radiologic technologists cohort study. Mult. Scler. 2019, 25, 1162-1169, doi:10.1177/1352458518783343.
120. Hedstrom, A.K.; Olsson, T.; Kockum, I.; Hillert, J.; Alfredsson, L. Low sun exposure increases multiple sclerosis risk both directly and indirectly. J. Neurol. 2019, 267, 1045-1052, doi:10.1007/s00415-019-09677-3.
121. Munger, K.L.; Levin, L.I.; Hollis, B.W.; Howard, N.S.; Ascherio, A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296, 2832-2838, doi:10.1001/jama.296.23.2832.
122. Bistrom, M.; Alonso-Magdalena, L.; Andersen, O.; Jons, D.; Gunnarsson, M.; Vrethem, M.; Hultdin, J.; Sundstrom, P. High serum concentration of vitamin D may protect against multiple sclerosis. Mult. Scler. J. Ex-p. Transl. Clin. 2019, 5, 2055217319892291, doi:10.1177/2055217319892291.
123. Nielsen, N.M.; Munger, K.L.; Koch-Henriksen, N.; Hougaard, D.M.; Magyari, M.; Jorgensen, K.T.; Lundqvist, M.; Simonsen, J.; Jess, T.; Cohen, A.; et al. Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study. Neurology 2017, 88, 44-51, doi:10.1212/WNL.0000000000003454.
124. Munger, K.L.; Zhang, S.M.; O'Reilly, E.; Hernan, M.A.; Olek, M.J.; Willett, W.C.; Ascherio, A. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62, 60-65, doi:10.1212/01.wnl.0000101723.79681.38.
125. Yeh, W.Z.; Gresle, M.; Jokubaitis, V.; Stankovich, J.; van der Walt, A.; Butzkueven, H. Immunoregulatory effects and therapeutic potential of vitamin D in multiple sclerosis. Br. J. Pharmacol. 2020, 177, 4113-4133, doi:10.1111/bph.15201.
126. Rhead, B.; Baarnhielm, M.; Gianfrancesco, M.; Mok, A.; Shao, X.; Quach, H.; Shen, L.; Schaefer, C.; Link, J.; Gyllenberg, A.; et al. Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk. Neurol. Genet. 2016, 2, e97, doi:10.1212/NXG.0000000000000097.
127. Baeke, F.; Takiishi, T.; Korf, H.; Gysemans, C.; Mathieu, C. Vitamin D: Modulator of the immune system. Curr. 〇-pin. Pharm. 2010, 10, 482-496, doi:10.1016/j.coph.2010.04.001.
128. Meftahi, G.H.; Jangravi, Z.; Sahraei, H.; Bahari, Z. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: The contribution of “inflame-aging”. Inflamm. Res. 2020, 69, 825-839, doi:10.1007/s00011-020-01372-8.
129. Cannell, J.J.; Vieth, R.; Umhau, J.C.; Holick, M.F.; Grant, W.B.; Madronich, S.; Garland, C.F.; Giovannucci, E. Epidemic influenza and vitamin D. Epidemiol. Infect. 2006, 134, 1129-1140, doi:10.1017/S0950268806007175.
130. Grant, W.B.; Giovannucci, E. The possible roles of solar ultraviolet-B radiation and vitamin D in reducing case-fatality rates from the 1918-1919 influenza pandemic in the United States. Dermatoendocrinol 2009, 1, 215-219.
131. Martineau, A.R.; Jolliffe, D.A.; Hooper, R.L.; Greenberg, L.; Aloia, J.F.; Bergman, P.; Dubnov-Raz, G.; Esposito, S.; Ganmaa, D.; Ginde, A.A.; et al. Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data. BMJ 2017, 356, i6583, doi:10.1136/bmj.i6583.
132. Aloia, J.F.; Li-Ng, M. Re: Epidemic influenza and vitamin D. Epidemiol. Infect. 2007, 135, 1095-1096, doi:10.1017/S0950268807008308.
133. Mercola, J.; Grant, W.B.; Wagner, C.L. Evidence Regarding Vitamin D and Risk of COVID-19 and Its Severity. Nutrients 2020, 12, doi:10.3390/nu12113361.
134. Millett, G.A.; Jones, A.T.; Benkeser, D.; Baral, S.; Mercer, L.; Beyrer, C.; Honermann, B.; Lankiewicz, E.; Mena, L.; Crowley, J.S.; et al. Assessing Differential Impacts of COVID-19 on Black Communities. Ann. Epidemiol. 2020, doi:10.1016/j.annepidem.2020.05.003.
135. CDC. Health Equity Considerations and Racial and Ethnic Minority Groups. Availabe online: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic-minorities.html (accessed on 6 September 2020).
136. Baktash, V.; Hosack, T.; Patel, N.; Shah, S.; Kandiah, P.; Van Den Abbeele, K.; Mandal, A.K.J.; Missouris, C.G. Vitamin D status and outcomes for hospitalised older patients with COVID-19. Postgrad. Med. J. 2020, doi:10.1136/postgradmedj-2020-138712.
137. Panagiotou, G.; Tee, S.A.; Ihsan, Y.I.; Athar, W.; Marchitelli, G.; Kelly, D.; Boot, C.S.; Stock, N.; Macfarlane, J.; Martineau, A.R.; et al. Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalised with COVID-19 are associated with greater disease severity: Results of a local audit of practice. Clin. Endocrinol. 2020, doi:10.1111/cen.14276.
138. Radujkovic, A.; Hippchen, T.; Tiwari-Heckler, S.; Dreher, S.; Boxberger, M.; Merle, U. Vitamin D Deficiency and Outcome of COVID-19 Patients. Nutrients 2020, 12, E2757, doi:10.3390/nu12092757.
139. French, C.B.; McDonnell, S.L.; Vieth, R. 25-Hydroxyvitamin D variability within-person due to diurnal rhythm and illness: A case report. J. Med. Case Rep. 2019, 13, 29, doi:10.1186/s13256-018-1948-9.
140. Smolders, J.; van den Ouweland, J.; Geven, C.; Pickkers, P.; Kox, M. Letter to the Editor: Vitamin D deficiency in COVID-19: Mixing up cause and consequence. Metabolism 2020, 154434, doi:10.1016/j.metabol.2020.154434.
141. Meltzer, D.O.; Best, T.J.; Zhang, H.; Vokes, T.; Arora, V.; Solway, J. Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results. JAMA Netw. Open 2020, 3, e2019722, doi:10.1001/jamanetworkopen.2020.19722.
142. Kaufman, H.W.; Niles, J.K.; Kroll, M.H.; Bi, C.; Holick, M.F. SARS-CoV-2 positivity rates associated with circulating 25- hydroxyvitamin D levels. PLoS ONE 2020, 15, e0239252, doi:10.1371/journal.pone.0239252.
143. Wang, R.; DeGruttola, V.; Ler, K.H.; Mayer, K.H.; Redline, S.; Hazra, A.; Mora, S.; Willett, W.C.; Gammaa, D.; Manson, J.E. The Vitamin D for COVID-19 (VIVID) Trial: A Pragmatic Cluster-Randomized Design. Contemp. Clin. Trials 2021, 100, 106176.
144. Entrenas Castillo, M.; Entrenas Costa, L.M.; Vaquero Barrios, J.M.; Alcala Diaz, J.F.; Miranda, J.L.; Bouillon, R.; Quesada Gomez, J.M. “Effect of Calcifediol Treatment and best Available Therapy versus best Available Therapy on Intensive Care Unit Admission and Mortality Among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical study”. J. Steroid. Biochem. Mol. Biol. 2020, 105751, doi:10.1016/j.jsbmb.2020.105751.
145. Rastogi, A.; Bhansali, A.; Khare, N.; Suri, V.; Yaddanapudi, N.; Sachdeva, N.; Puri, G.D.; Malhotra, P. Short term, high-dose vitamin D supplementation for COVID-19 disease: A randomised, placebo-controlled, study (SHADE study). Postgrad. Med. J. 2020, doi:10.1136/postgradmedj-2020-139065.
146. ClinicalTrials.Gov. Studies for Vitamin D, COVID19. Availabe online: https://clinicaltrials.gov/ct2/results?cond=COVID19&term=vitamin+D&cntry=&state=&city=&dist= (accessed on 30 December 2020).
147. Wolsk, H.M.; Chawes, B.L.; Litonjua, A.A.; Hollis, B.W.; Waage, J.; Stokholm, J.; Bonnelykke, K.; Bisgaard, H.; Weiss, S.T. Prenatal vitamin D supplementation reduces risk of asthma/recurrent wheeze in early childhood: A combined analysis of two randomized controlled trials. PLoS ONE 2017, 12, e0186657, doi:10.1371/journal.pone.0186657.
148. Wolsk, H.M.; Harshfield, B.J.; Laranjo, N.; Carey, V.J.; O'Connor, G.; Sandel, M.; Strunk, R.C.; Bacharier, L.B.; Zeiger, R.S.; Schatz, M.; et al. Vitamin D supplementation in pregnancy, prenatal 25(OH)D levels, race, and subsequent asthma or recurrent wheeze in offspring: Secondary analyses from the Vitamin D Antenatal Asthma Reduction Trial. J. Allergy Clin. Immunol. 2017, 140, 1423-1429 e1425, doi:10.1016/j.jaci.2017.01.013.
149. Jolliffe, D.A.; Greenberg, L.; Hooper, R.L.; Griffiths, C.J.; Camargo, C.A., Jr.; Kerley, C.P.; Jensen, M.E.; Mauger, D.; Stelmach, I.; Urashima, M.; et al. Vitamin D supplementation to prevent asthma exacerbations: A systematic review and meta-analysis of individual participant data. Lancet. Respir. Med. 2017, 5, 881-890, doi:10.1016/S2213-2600(17)30306-5.
150. Cunningham, T.J.; Croft, J.B.; Liu, Y.; Lu, H.; Eke, P.I.; Giles, W.H. Vital Signs: Racial Disparities in Age-Specific Mortality Among Blacks or African Americans—United States, 1999-2015. Mmwr. Morb. Mortal. Wkly. Rep. 2017, 66, 444-456, doi:10.15585/mmwr.mm6617e1.
151. Ford, M.E.; Magwood, G.; Brown, E.T.; Cannady, K.; Gregoski, M.; Knight, K.D.; Peterson, L.L.; Kramer, R.; Evans-Knowell, A.; Turner, D.P. Disparities in Obesity, Physical Activity Rates, and Breast Cancer Survival. Adv. Cancer Res. 2017, 133, 23-50, doi:10.1016/bs.acr.2016.08.002.
152. Musemwa, N.; Gadegbeku, C.A. Hypertension in African Americans. Curr. Cardiol. Rep. 2017, 19, 129, doi:10.1007/s11886-017- 0933-z.
153. Reeder-Hayes, K.E.; Troester, M.A.; Meyer, A.M. Reducing Racial Disparities in Breast Cancer Care: The Role of 'Big Data'. Oncology (Williston Park) 2017, 31, 756-762.
154. Singh, G.K.; Daus, G.P.; Allender, M.; Ramey, C.T.; Martin, E.K.; Perry, C.; Reyes, A.A.L.; Vedamuthu, I.P. Social Determinants of Health in the United States: Addressing Major Health Inequality Trends for the Nation, 1935-2016. Int. J. MCH AIDS 2017, 6, 139-164, doi:10.21106/ijma.236.
155. Wilcox, S.; Sharpe, P.A.; Liese, A.D.; Dunn, C.G.; Hutto, B. Socioeconomic factors associated with diet quality and meeting dietary guidelines in disadvantaged neighborhoods in the Southeast United States. Ethn. Health 2018, 1-17, doi:10.1080/13557858.2018.1493434.
156. Gaksch, M.; Jorde, R.; Grimnes, G.; Joakimsen, R.; Schirmer, H.; Wilsgaard, T.; Mathiesen, E.B.; Njolstad, I.; Lochen, M.L.; Marz, W.; et al. Vitamin D and mortality: Individual participant data meta-analysis of standardized 25-hydroxyvitamin D in 26916 individuals from a European consortium. PLoS ONE 2017, 12, e0170791, doi:10.1371/journal.pone.0170791.
157. Garland, C.F.; Kim, J.J.; Mohr, S.B.; Gorham, E.D.; Grant, W.B.; Giovannucci, E.L.; Baggerly, L.; Hofflich, H.; Ramsdell, J.W.; Zeng, K.; et al. Meta-analysis of all-cause mortality according to serum 25-hydroxyvitamin D. Am. J. Public Health 2014, 104, e43-e50, doi:10.2105/AJPH.2014.302034.
158. Meng, X.; Li, X.; Timofeeva, M.N.; He, Y.; Spiliopoulou, A.; Wei, W.Q.; Gifford, A.; Wu, H.; Varley, T.; Joshi, P.; et al. Phenome- wide Mendelian-randomization study of genetically determined vitamin D on multiple health outcomes using the UK Biobank study. Int. J. Epidemiol. 2019, 48, 1425-1434, doi:10.1093/ije/dyz182.
159. Kritchevsky, S.B.; Tooze, J.A.; Neiberg, R.H.; Schwartz, G.G.; Hausman, D.B.; Johnson, M.A.; Bauer, D.C.; Cauley, J.A.; Shea, M.K.; Cawthon, P.M.; et al. 25-Hydroxyvitamin D, parathyroid hormone, and mortality in black and white older adults: The health ABC study. J. Clin. Endocrinol. Metab. 2012, 97, 4156-4165, doi:10.1210/jc.2012-1551.
160. Signorello, L.B.; Han, X.; Cai, Q.; Cohen, S.S.; Cope, E.L.; Zheng, W.; Blot, W.J. A prospective study of serum 25-hydroxyvitamin d levels and mortality among African Americans and non-African Americans. Am. J. Epidemiol. 2013, 177, 171-179, doi:10.1093/aje/kws348.
161. Schleicher, R.L.; Sternberg, M.R.; Looker, A.C.; Yetley, E.A.; Lacher, D.A.; Sempos, C.T.; Taylor, C.L.; Durazo-Arvizu, R.A.; Maw, K.L.; Chaudhary-Webb, M.; et al. National Estimates of Serum Total 25-Hydroxyvitamin D and Metabolite Concentrations Measured by Liquid Chromatography-Tandem Mass Spectrometry in the US Population during 2007-2010. J. Nutr. 2016, 146, 1051-1061, doi:10.3945/jn.115.227728.
162. Heaney, R.P. Guidelines for optimizing design and analysis of clinical studies of nutrient effects. Nutr. Rev. 2014, 72, 48-54, doi:10.1111/nure.12090.
163. Grant, W.B.; Boucher, B.J.; Bhattoa, H.P.; Lahore, H. Why vitamin D clinical trials should be based on 25-hydroxyvitamin D concentrations. J. Steroid Biochem. Mol. Biol. 2018, 177, 266-269, doi:10.1016/j.jsbmb.2017.08.009.
164. Rollins, L.; Sy, A.; Crowell, N.; Rivers, D.; Miller, A.; Cooper, P.; Teague, D.; Jackson, C.; Henry Akintobi, T.; Ofili, E. Learning and Action in Community Health: Using the Health Belief Model to Assess and Educate African American Community Residents about Participation in Clinical Research. Int. J. Environ. Res. Public Health 2018, 15, 1862, doi:10.3390/ijerph15091862.
165. Grant, W.B.; Boucher, B.J. Why Secondary Analyses in Vitamin D Clinical Trials Are Important and How to Improve Vitamin D Clinical Trial Outcome Analyses-A Comment on “Extra-Skeletal Effects of Vitamin D, Nutrients 2019, 11, 1460”. Nutrients 2019, 11, 2182, doi:10.3390/nu11092182.
166. McDonnell, S.L.; Baggerly, C.A.; French, C.B.; Baggerly, L.L.; Garland, C.F.; Gorham, E.D.; Hollis, B.W.; Trump, D.L.; Lappe,
167. J.M. Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations > 60 vs < 20 ng/mL (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort. PLoS ONE 2018, 13, e0199265, #doi:10.1371/journal.pone.0199265.
168. Migliaccio, S.; Di Nisio, A.; Mele, C.; Scappaticcio, L.; Savastano, S.; Colao, A.; Obesity Programs of nutrition, E.R.; Assessment, G. Obesity and hypovitaminosis D: Causality or casualty? Int. J. Obes. Suppl. 2019, 9, 20-31, doi:10.1038/s41367-019-0010-8.
169. Freedman, D.M.; Cahoon, E.K.; Rajaraman, P.; Major, J.M.; Doody, M.M.; Alexander, B.H.; Hoffbeck, R.W.; Kimlin, M.G.; Graubard, B.I.; Linet, M.S. Sunlight and other determinants of circulating 25-hydroxyvitamin D levels in black and white participants in a nationwide U.S. study. Am. J. Epidemiol. 2013, 177, 180-192, doi:10.1093/aje/kws223.
170. Bailey, R.K.; Fileti, C.P.; Keith, J.; Tropez-Sims, S.; Price, W.; Allison-Ottey, S.D. Lactose intolerance and health disparities among African Americans and Hispanic Americans: An updated consensus statement. J. Natl. Med. Assoc. 2013, 105, 112-127, doi:10.1016/s0027-9684(15)30113-9.
171. McCullough, M.L.; Zoltick, E.S.; Weinstein, S.J.; Fedirko, V.; Wang, M.; Cook, N.R.; Eliassen, A.H.; Zeleniuch-Jacquotte, A.; Agnoli, C.; Albanes, D.; et al. Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts. J. Natl. Cancer Inst. 2019, 111, 158-169, doi:10.1093/jnci/djy087.
172. Bischoff-Ferrari, H.A.; Kiel, D.P.; Dawson-Hughes, B.; Orav, J.E.; Li, R.; Spiegelman, D.; Dietrich, T.; Willett, W.C. Dietary calcium and serum 25-hydroxyvitamin D status in relation to BMD among U.S. adults. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2009, 24, 935-942, doi:10.1359/jbmr.081242.
173. McDonnell, S.L.; Baggerly, C.; French, C.B.; Baggerly, L.L.; Garland, C.F.; Gorham, E.D.; Lappe, J.M.; Heaney, R.P. Serum 25- Hydroxyvitamin D Concentrations >40 ng/ml Are Associated with >65% Lower Cancer Risk: Pooled Analysis of Randomized Trial and Prospective Cohort Study. PLoS ONE 2016, 11, e0152441, doi:10.1371/journal.pone.0152441.
174. Mirhosseini, N.; Vatanparast, H.; Kimball, S.M. The Association between Serum 25(OH)D Status and Blood Pressure in Participants of a Community-Based Program Taking Vitamin D Supplements. Nutrients 2017, 9, E1244, doi:10.3390/nu9111244.
175. Raed, A.; Bhagatwala, J.; Zhu, H.; Pollock, N.K.; Parikh, S.J.; Huang, Y.; Havens, R.; Kotak, I.; Guo, D.H.; Dong, Y. Dose responses of vitamin D3 supplementation on arterial stiffness in overweight African Americans with vitamin D deficiency: A placebo controlled randomized trial. PLoS ONE 2017, 12, e0188424, doi:10.1371/journal.pone.0188424.
176. Ng, K.; Scott, J.B.; Drake, B.F.; Chan, A.T.; Hollis, B.W.; Chandler, P.D.; Bennett, G.G.; Giovannucci, E.L.; Gonzalez-Suarez, E.; Meyerhardt, J.A.; et al. Dose response to vitamin D supplementation in African Americans: Results of a 4-arm, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 2014, 99, 587-598, doi:10.3945/ajcn.113.067777.
177. Garrett-Mayer, E.; Wagner, C.L.; Hollis, B.W.; Kindy, M.S.; Gattoni-Celli, S. Vitamin D3 supplementation (4000 IU/d for 1 y) eliminates differences in circulating 25-hydroxyvitamin D between African American and white men. Am. J. Clin. Nutr. 2012, 96, 332-336, doi:10.3945/ajcn.112.034256.
178. Kantor, E.D.; Rehm, C.D.; Du, M.; White, E.; Giovannucci, E.L. Trends in Dietary Supplement Use Among US Adults From 1999-2012. JAMA 2016, 316, 1464-1474, doi:10.1001/jama.2016.14403.
179. Carlberg, C.; Haq, A. The concept of the personal vitamin D response index. J. Steroid Biochem. Mol. Biol. 2018, 175, 12-17, doi:10.1016/j.jsbmb.2016.12.011.
180. Carlberg, C. Nutrigenomics of Vitamin D. Nutrients 2019, 11, doi:10.3390/nu11030676.
181. Malihi, Z.; Wu, Z.; Lawes, C.M.M.; Scragg, R. Adverse events from large dose vitamin D supplementation taken for one year or longer. J. Steroid Biochem. Mol. Biol. 2019, 188, 29-37, doi:10.1016/j.jsbmb.2018.12.002.
182. Araki, T.; Holick, M.F.; Alfonso, B.D.; Charlap, E.; Romero, C.M.; Rizk, D.; Newman, L.G. Vitamin D intoxication with severe hypercalcemia due to manufacturing and labeling errors of two dietary supplements made in the United States. J. Clin. Endocrinol. Metab. 2011, 96, 3603-3608, doi:10.1210/jc.2011-1443.
183. Taylor, P.N.; Davies, J.S. A review of the growing risk of vitamin D toxicity from inappropriate practice. Br. J. Clin. Pharmacol. 2018, 84, 1121-1127, doi:10.1111/bcp.13573.
184. Schulster, M.L.; Goldfarb, D.S. Vitamin D and Kidney Stones. Urology 2020, 139, 1-7, doi:10.1016/j.urology.2020.01.030